What is OptimizeRx's operating income?

OptimizeRx's total operating income in 2025 was $11.69 million, based on the following breakdown: Total Gross Profit: $73.60 million Total Operating Expenses: $61.90 million

OptimizeRx (OPRX) Financials

$6.28 +0.13 (+2.11%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$6.30 +0.02 (+0.32%)

As of 04:42 AM Eastern

Compare

Annual Income Statements for OptimizeRx

This table shows OptimizeRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-0.60	-1.54	-2.10	0.23	-3.14	-2.28	0.38	-11	-18	-20	5.13
Consolidated Net Income / (Loss)	-0.60	-1.54	-2.10	0.23	-3.14	-2.21	0.38	-11	-18	-20	5.13
Net Income / (Loss) Continuing Operations	-0.60	-1.54	-2.10	0.23	-3.14	-2.28	0.38	-11	-18	-20	5.13
Total Pre-Tax Income	-0.60	-1.54	-2.10	0.23	-4.04	-2.21	0.38	-11	-25	-19	6.95
Total Operating Income	-0.60	-1.58	-2.13	0.18	-3.69	-2.14	0.36	-12	-26	-14	12
Total Gross Profit	3.60	4.34	5.95	12	15	24	36	39	43	59	74
Total Revenue	3.60	4.34	5.95	21	25	43	61	62	72	92	109
Operating Revenue	3.60	4.34	5.95	21	25	43	61	62	72	92	109
Total Cost of Revenue	0.00	0.00	0.00	9.00	9.16	19	26	23	29	33	36
Operating Cost of Revenue	-	-	-	9.00	9.16	19	26	23	29	33	36
Total Operating Expenses	4.20	5.92	8.08	12	19	26	35	51	67	73	62
Selling, General & Admin Expense	3.28	5.08	6.86	9.19	16	21	28	33	44	50	50
Depreciation Expense	0.33	0.24	0.32	0.32	1.28	2.08	2.09	2.02	2.40	4.33	4.33
Other Operating Expenses / (Income)	0.58	0.56	0.90	2.52	2.26	3.17	-	-	-	11	6.96
Impairment Charge	-	-	-	-	-	-	-	0.00	6.74	7.49	0.37
Total Other Income / (Expense), net	0.00	0.04	0.03	0.05	-0.35	-0.14	0.02	0.85	-0.90	-5.68	-4.74
Interest Expense	0.00	-	-	-	-	-	-	0.00	1.45	6.16	5.29
Interest & Investment Income	0.00	0.04	0.03	0.05	0.29	0.07	-	0.85	2.19	0.33	0.35
Other Income / (Expense), net	-	-	-	0.00	-0.64	-0.21	0.02	0.00	-1.64	0.15	0.20
Income Tax Expense	0.00	0.00	0.00	-	-0.90	0.00	0.00	0.00	-7.60	0.73	1.82
Basic Earnings per Share	($0.02)	($0.05)	($0.21)	-	($0.23)	($0.15)	$0.02	($0.64)	($1.03)	($1.10)	$0.28
Weighted Average Basic Shares Outstanding	24.56M	29.71M	9.82M	10.83M	13.39M	14.83M	17.23M	17.78M	17.12M	18.29M	18.56M
Diluted Earnings per Share	($0.02)	($0.05)	($0.21)	-	($0.23)	($0.15)	$0.02	($0.64)	($1.03)	($1.10)	$0.27
Weighted Average Diluted Shares Outstanding	29.03M	29.71M	9.82M	11.86M	13.39M	14.83M	17.69M	17.78M	17.12M	18.29M	19.00M
Weighted Average Basic & Diluted Shares Outstanding	29.03M	29.71M	29.46M	12.10M	14.64M	16.81M	17.88M	17.10M	-	-	18.76M

This table shows OptimizeRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-2.87	-4.14	-6.90	-4.01	-9.12	-0.08	-2.20	1.53	0.78	5.02	-0.50
Consolidated Net Income / (Loss)	-2.87	-4.14	-6.90	-4.01	-9.12	-0.08	-2.20	1.53	0.78	5.02	-0.50
Net Income / (Loss) Continuing Operations	-2.87	-4.14	-6.90	-4.01	-9.12	-0.08	-2.20	1.53	0.78	5.02	-0.50
Total Pre-Tax Income	-2.87	-12	-6.56	-5.10	-9.94	2.21	-3.27	1.71	1.05	7.47	-0.64
Total Operating Income	-3.55	-11	-5.03	-3.75	-8.56	3.63	-2.10	3.19	2.05	8.57	0.40
Total Gross Profit	9.80	18	12	12	13	22	13	19	18	24	15
Total Revenue	16	28	20	19	21	32	22	29	26	32	20
Operating Revenue	16	28	20	19	21	32	22	29	26	32	20
Total Cost of Revenue	6.53	11	7.49	7.11	7.86	10	8.58	11	8.55	8.14	4.91
Operating Cost of Revenue	6.53	11	7.49	7.11	7.86	10	8.58	11	8.55	8.14	4.91
Total Operating Expenses	13	27	17	15	22	18	15	15	15	16	15
Selling, General & Admin Expense	13	5.18	16	14	13	5.83	4.56	14	14	7.12	3.51
Marketing Expense	-	-	-	-	-	-	4.99	-	-	-	4.73
Research & Development Expense	-	-	-	-	-	-	3.25	-	-	-	3.40
Depreciation Expense	0.47	1.01	1.07	1.07	1.10	1.09	1.09	1.07	1.08	1.08	1.06
Other Operating Expenses / (Income)	-	-	-	-	-	-	1.56	-	-	-	1.83
Total Other Income / (Expense), net	0.69	-2.98	-1.53	-1.35	-1.38	-1.43	-1.17	-1.48	-1.00	-1.10	-1.04
Interest Expense	0.00	-	1.55	1.53	1.52	1.56	1.30	1.60	1.15	1.24	1.16
Interest & Investment Income	0.69	0.12	0.02	0.11	0.11	0.10	0.09	0.09	0.09	0.08	0.08
Other Income / (Expense), net	0.00	-	0.00	0.08	0.04	-	0.04	0.04	0.06	0.06	0.04
Income Tax Expense	0.00	-7.63	0.34	-1.09	-0.82	2.29	-1.07	0.18	0.27	2.45	-0.15
Basic Earnings per Share	($0.17)	($0.25)	($0.38)	($0.22)	($0.50)	-	($0.12)	$0.08	$0.04	$0.28	($0.03)
Weighted Average Basic Shares Outstanding	16.64M	17.12M	18.17M	18.26M	18.32M	18.29M	18.47M	18.51M	18.58M	18.56M	18.76M
Diluted Earnings per Share	($0.17)	($0.25)	($0.38)	($0.22)	($0.50)	-	($0.12)	$0.08	$0.04	$0.27	($0.03)
Weighted Average Diluted Shares Outstanding	16.64M	17.12M	18.17M	18.26M	18.32M	18.29M	18.47M	19.02M	19.46M	19.00M	18.76M
Weighted Average Basic & Diluted Shares Outstanding	18.15M	0.00	18.27M	18.32M	-	0.00	18.50M	18.57M	18.64M	18.76M	18.77M

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	4.76	-1.17	-1.91	3.79	9.94	-8.34	74	-66	-4.36	-0.47	9.99
Net Cash From Operating Activities	0.52	-0.47	-1.48	0.79	-1.66	-6.31	0.73	11	-7.24	4.89	19
Net Cash From Continuing Operating Activities	0.52	-0.47	-1.48	0.79	-1.66	-6.31	0.73	11	-7.24	4.89	19
Net Income / (Loss) Continuing Operations	-0.60	-1.54	-2.10	0.23	-3.14	-2.21	0.38	-11	-18	-20	5.13
Consolidated Net Income / (Loss)	-0.60	-1.54	-2.10	0.23	-3.14	-2.21	0.38	-11	-18	-20	5.13
Depreciation Expense	0.33	0.24	0.32	0.32	1.18	1.97	1.97	2.02	2.40	4.33	4.33
Amortization Expense	-	-	-	-	-	-	-	0.00	0.21	0.84	1.11
Non-Cash Adjustments To Reconcile Net Income	1.47	0.83	-0.03	3.25	1.26	3.48	5.57	16	23	19	5.36
Changes in Operating Assets and Liabilities, net	-0.69	0.01	0.33	-3.00	-0.95	-9.55	-7.19	3.96	-16	1.12	2.78
Net Cash From Investing Activities	-0.10	-0.35	-0.04	-5.69	-11	-0.12	-0.49	-58	-25	-0.45	0.07
Net Cash From Continuing Investing Activities	-0.10	-0.35	-0.04	-5.69	-11	-0.12	-0.49	-58	-25	-0.45	0.07
Purchase of Property, Plant & Equipment	-0.00	-0.18	-0.04	-0.03	-0.09	-0.11	-0.46	-0.24	-0.87	-0.45	0.07
Net Cash From Financing Activities	4.35	-0.36	-0.39	8.69	22	-1.90	74	-19	28	-4.91	-8.80
Net Cash From Continuing Financing Activities	4.35	-0.36	-0.39	8.69	22	-1.90	74	-19	28	-4.91	-8.80
Repayment of Debt	-	-	-	-	-	-	-	0.00	-1.71	-4.00	-8.00
Other Financing Activities, net	-	-	0.00	0.52	0.88	-1.90	3.25	1.07	-0.28	-0.91	-0.80
Cash Interest Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.21	6.20	4.18
Cash Income Taxes Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.16	1.76

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.12	3.93	1.33	-0.22	1.17	-2.75	3.19	0.01	2.93	3.85	-3.20
Net Cash From Operating Activities	1.47	-6.26	2.12	0.78	1.79	0.20	3.86	4.56	3.20	7.09	-0.47
Net Cash From Continuing Operating Activities	1.47	-6.26	2.12	0.78	1.79	0.20	3.86	4.56	3.20	7.09	-0.47
Net Income / (Loss) Continuing Operations	-2.87	-4.14	-6.90	-4.01	-9.12	-0.08	-2.20	1.53	0.78	5.02	-0.50
Consolidated Net Income / (Loss)	-2.87	-4.14	-6.90	-4.01	-9.12	-0.08	-2.20	1.53	0.78	5.02	-0.50
Depreciation Expense	0.47	1.01	1.07	1.07	1.10	1.09	1.09	1.07	1.08	1.08	1.06
Amortization Expense	-	0.21	0.18	0.18	0.18	0.29	0.17	0.44	0.17	0.33	0.36
Non-Cash Adjustments To Reconcile Net Income	4.71	12	0.46	2.18	11	3.01	-1.75	2.34	1.69	3.09	1.83
Changes in Operating Assets and Liabilities, net	-0.84	-15	7.30	1.35	-1.57	-4.12	6.55	-0.82	-0.53	-2.42	-3.22
Net Cash From Investing Activities	-1.01	-26	-0.15	-0.09	-0.09	-0.12	-0.08	-0.04	-0.01	0.21	-0.02
Net Cash From Continuing Investing Activities	-1.01	-26	-0.15	-0.09	-0.09	-0.12	-0.08	-0.04	-0.01	0.21	-0.02
Purchase of Property, Plant & Equipment	-0.32	0.77	-0.15	-0.09	-0.09	-0.12	-0.08	-0.04	-0.01	0.21	-0.02
Net Cash From Financing Activities	-0.35	36	-0.64	-0.92	-0.53	-2.82	-0.59	-4.51	-0.26	-3.45	-2.71
Net Cash From Continuing Financing Activities	-0.35	36	-0.64	-0.92	-0.53	-2.82	-0.59	-4.51	-0.26	-3.45	-2.71
Repayment of Debt	-0.30	-1.41	-0.50	-0.50	-0.50	-2.50	-0.50	-4.50	-0.50	-2.50	-2.69
Other Financing Activities, net	-0.05	-0.13	-0.14	-0.42	-0.03	-0.32	-0.09	-0.01	0.24	-0.95	-0.02
Cash Interest Paid	-	1.21	1.35	1.36	1.37	2.12	1.12	1.17	0.98	0.92	0.80
Cash Income Taxes Paid	-	0.05	0.02	0.09	-0.11	0.16	0.00	1.09	-0.08	0.75	0.01

This table presents OptimizeRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	11	9.76	25	57	60	141	135	183	171	177
Total Current Assets	11	10	8.81	16	27	33	115	99	54	54	65
Cash & Equivalents	8.21	7.03	5.12	8.91	19	11	85	18	14	13	23
Accounts Receivable	2.85	3.06	3.43	6.46	7.42	18	25	22	36	38	38
Prepaid Expenses	0.07	0.08	0.26	0.36	0.87	4.46	5.63	2.28	3.19	2.38	2.85
Current Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	0.00	1.04	0.00	0.75
Plant, Property, & Equipment, net	0.01	0.17	0.17	0.15	0.18	0.15	0.14	0.14	0.15	0.15	0.11
Total Noncurrent Assets	1.18	1.13	0.79	9.17	29	27	51	36	129	117	112
Goodwill	-	-	0.00	3.68	15	15	15	23	78	71	71
Intangible Assets	1.17	1.12	0.78	5.15	5.15	4.52	3.90	3.38	34	37	29
Other Noncurrent Operating Assets	0.01	0.01	0.01	0.34	9.43	8.06	33	9.88	16	8.84	12
Total Liabilities & Shareholders' Equity	12	11	9.76	25	57	60	141	135	183	171	177
Total Liabilities	3.37	3.67	3.54	6.60	12	10	9.61	8.54	57	54	49
Total Current Liabilities	3.37	3.67	3.54	4.23	6.11	10	9.37	8.40	18	19	21
Short-Term Debt	-	-	-	-	-	-	-	0.00	2.00	2.00	4.26
Accounts Payable	0.78	0.37	0.46	0.41	0.49	0.62	0.61	1.55	2.23	2.16	1.64
Accrued Expenses	0.01	0.29	0.95	1.30	1.80	2.42	2.90	2.60	7.71	8.49	12
Current Deferred Revenue	0.23	0.39	0.51	0.61	0.58	0.29	1.39	0.16	0.17	0.47	0.50
Other Current Liabilities	2.36	2.62	1.62	1.91	3.23	6.70	4.47	4.08	5.73	5.22	3.28
Total Noncurrent Liabilities	0.00	0.00	0.00	2.37	5.67	0.33	0.24	0.14	39	36	27
Long-Term Debt	-	-	-	-	-	-	-	0.00	34	31	21
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	0.00	4.34	4.49	5.71
Other Noncurrent Operating Liabilities	-	-	0.00	2.37	5.67	0.33	0.24	0.14	0.37	0.21	0.23
Commitments & Contingencies	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.94	7.81	6.22	18	45	50	131	126	127	117	128
Total Preferred & Common Equity	8.94	7.81	6.22	18	45	50	131	126	127	117	128
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8.94	7.81	6.22	18	45	50	131	126	127	117	128
Common Stock	32	34	35	49	78	86	167	173	191	201	208
Retained Earnings	-27	-28	-30	-30	-33	-36	-35	-47	-64	-84	-79
Treasury Stock	-	-	-	-	-	-	0.00	-0.00	-0.00	-	-0.00

This table presents OptimizeRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	124	176	173	165	168	169	170	167
Total Current Assets	87	48	46	47	52	54	56	56
Cash & Equivalents	9.92	15	15	16	17	17	20	20
Accounts Receivable	21	30	25	26	33	34	32	32
Prepaid Expenses	3.01	2.39	4.65	4.39	2.31	3.34	2.83	3.14
Current Deferred & Refundable Income Taxes	-	1.04	1.84	0.06	0.11	0.65	1.75	0.87
Plant, Property, & Equipment, net	0.15	0.15	0.17	0.16	0.15	0.13	0.12	0.11
Total Noncurrent Assets	36	128	127	118	116	115	114	111
Goodwill	23	78	78	71	71	71	71	71
Intangible Assets	4.92	48	47	38	37	36	35	33
Other Noncurrent Operating Assets	8.00	0.53	0.47	9.17	8.46	8.37	7.96	6.95
Total Liabilities & Shareholders' Equity	124	176	173	165	168	169	170	167
Total Liabilities	7.82	54	52	51	51	50	48	38
Total Current Liabilities	7.70	17	15	15	18	21	18	10
Short-Term Debt	-	3.50	3.30	2.00	3.30	3.30	3.30	2.00
Accounts Payable	0.69	1.67	2.98	2.75	3.38	1.98	2.04	3.07
Accrued Expenses	3.11	7.28	5.31	5.56	9.28	12	10	3.59
Current Deferred Revenue	0.19	0.90	1.05	0.79	0.51	0.48	0.40	0.67
Other Current Liabilities	3.71	3.05	2.31	3.41	1.88	2.80	2.54	1.13
Total Noncurrent Liabilities	0.12	37	37	36	33	29	30	27
Long-Term Debt	-	32	32	33	29	25	25	21
Noncurrent Deferred & Payable Income Tax Liabilities	-	4.34	4.34	2.71	3.79	3.46	4.49	5.66
Other Noncurrent Operating Liabilities	0.12	-	-	0.24	0.17	0.34	0.30	0.20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	116	123	121	114	116	119	122	130
Total Preferred & Common Equity	116	123	121	114	116	119	122	130
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	116	123	121	114	116	119	122	130
Common Stock	176	194	196	199	203	204	207	209
Retained Earnings	-60	-71	-75	-84	-87	-85	-84	-80
Treasury Stock	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	29,018,425.00	29,672,132.00	29,275,117.00	12,013,682.00	14,173,850.00	15,108,646.00	17,769,544.00	17,152,717.00	18,152,478.00	-	18,640,652.00
DEI Adjusted Shares Outstanding	29,018,425.00	29,672,132.00	29,275,117.00	12,013,682.00	14,173,850.00	15,108,646.00	17,769,544.00	17,152,717.00	18,152,478.00	-	18,640,652.00
DEI Earnings Per Adjusted Shares Outstanding	-0.02	-0.05	-0.07	0.02	-0.22	-0.15	0.02	-0.67	-0.97	-	0.28
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.66%	20.61%	37.16%	256.24%	15.99%	76.08%	41.51%	1.89%	14.53%	28.81%	18.78%
EBITDA Growth	65.43%	-410.99%	-34.11%	127.51%	-734.96%	88.06%	722.53%	-538.20%	-147.66%	67.01%	306.53%
EBIT Growth	41.79%	-164.73%	-34.68%	108.46%	-2,503.00%	45.77%	116.11%	-3,350.84%	-128.17%	51.67%	187.73%
NOPAT Growth	41.79%	-164.73%	-34.68%	112.08%	-1,535.33%	42.19%	124.16%	-2,482.59%	-114.81%	48.09%	190.00%
Net Income Growth	41.96%	-158.63%	-36.70%	110.76%	-1,488.41%	29.77%	117.13%	-3,125.41%	-53.57%	-14.48%	125.52%
EPS Growth	50.00%	-150.00%	-320.00%	0.00%	0.00%	34.78%	113.33%	-3,300.00%	-60.94%	-6.80%	124.55%
Operating Cash Flow Growth	1,014.13%	-190.46%	-217.58%	153.56%	-309.55%	-279.96%	111.51%	1,367.43%	-167.96%	167.53%	282.80%
Free Cash Flow Firm Growth	100.75%	-11,602.23%	-57.56%	-356.35%	-130.46%	21.57%	-118.23%	136.35%	-1,074.00%	102.52%	398.08%
Invested Capital Growth	-36.81%	5.80%	41.21%	769.28%	172.51%	51.70%	83.56%	-28.24%	186.57%	-8.39%	-4.27%
Revenue Q/Q Growth	30.87%	4.90%	50.44%	23.65%	3.36%	26.40%	6.77%	-1.04%	13.88%	4.48%	-0.07%
EBITDA Q/Q Growth	-170.62%	2.70%	8.09%	45.50%	-446.96%	90.14%	-24.01%	-20.26%	-75.66%	63.96%	40.29%
EBIT Q/Q Growth	-1,316.15%	2.95%	5.70%	171.80%	-193.35%	59.60%	-65.52%	-17.18%	-71.74%	52.07%	71.44%
NOPAT Q/Q Growth	-951.30%	2.95%	5.70%	171.80%	-146.15%	63.25%	-67.07%	-13.75%	-61.68%	51.53%	6,422.76%
Net Income Q/Q Growth	-1,280.97%	3.86%	5.21%	128.17%	-147.89%	60.23%	-65.99%	-9.05%	-27.75%	16.81%	15,451.52%
EPS Q/Q Growth	-300.00%	-25.00%	-31.25%	0.00%	0.00%	61.54%	-71.43%	-12.28%	-27.16%	18.52%	0.00%
Operating Cash Flow Q/Q Growth	-32.29%	-1,887.14%	22.13%	687.10%	-315.16%	-20.94%	236.47%	63.51%	-497.48%	412.17%	58.27%
Free Cash Flow Firm Q/Q Growth	-98.27%	-112.30%	15.90%	-220.93%	-104.05%	44.13%	-441.84%	171.50%	-829.43%	102.86%	397.98%
Invested Capital Q/Q Growth	-31.01%	66.80%	5.66%	159.28%	117.34%	13.88%	73.43%	2.36%	187.71%	2.11%	-0.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	57.56%	62.77%	55.65%	58.14%	62.40%	59.98%	64.45%	67.25%
EBITDA Margin	-7.32%	-31.02%	-30.33%	2.34%	-12.82%	-0.87%	3.82%	-16.44%	-35.56%	-9.11%	15.83%
Operating Margin	-16.60%	-36.44%	-35.78%	0.85%	-15.02%	-4.93%	0.59%	-19.68%	-36.91%	-14.88%	10.69%
EBIT Margin	-16.60%	-36.44%	-35.78%	0.85%	-17.60%	-5.42%	0.62%	-19.68%	-39.21%	-14.71%	10.87%
Profit (Net Income) Margin	-16.54%	-35.47%	-35.35%	1.07%	-12.78%	-5.10%	0.62%	-18.32%	-24.56%	-21.83%	4.69%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	77.78%	100.00%	100.00%	100.00%	69.81%	103.74%	73.84%
Interest Burden Percent	99.62%	97.32%	98.78%	125.65%	93.35%	94.02%	100.00%	93.07%	89.73%	143.02%	58.45%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	26.16%
Return on Invested Capital (ROIC)	-44.06%	-146.39%	-159.00%	3.39%	-14.54%	-4.57%	0.65%	-13.83%	-18.40%	-6.72%	6.47%
ROIC Less NNEP Spread (ROIC-NNEP)	-41.03%	-140.72%	-148.91%	2.73%	-10.53%	0.29%	0.60%	-9.57%	-21.94%	-57.02%	-25.74%
Return on Net Nonoperating Assets (RNNOA)	35.28%	128.02%	129.01%	-1.55%	4.62%	-0.09%	-0.23%	4.95%	4.49%	-9.79%	-2.28%
Return on Equity (ROE)	-8.78%	-18.37%	-29.99%	1.83%	-9.93%	-4.65%	0.42%	-8.88%	-13.90%	-16.51%	4.18%
Cash Return on Invested Capital (CROIC)	1.05%	-152.02%	-193.17%	-155.35%	-107.16%	-45.65%	-58.29%	19.06%	-114.92%	2.04%	10.83%
Operating Return on Assets (OROA)	-6.18%	-13.29%	-20.05%	1.03%	-10.60%	-4.01%	0.38%	-8.92%	-17.64%	-7.65%	6.83%
Return on Assets (ROA)	-6.15%	-12.94%	-19.81%	1.30%	-7.69%	-3.77%	0.38%	-8.30%	-11.05%	-11.34%	2.95%
Return on Common Equity (ROCE)	-8.78%	-18.37%	-29.99%	1.83%	-9.93%	-4.65%	0.42%	-8.88%	-13.90%	-16.51%	4.18%
Return on Equity Simple (ROE_SIMPLE)	-6.66%	-19.70%	-33.82%	1.23%	-7.00%	-4.42%	0.29%	-9.07%	-13.88%	-17.19%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.42	-1.11	-1.49	0.18	-2.59	-1.49	0.36	-8.60	-18	-9.59	8.63
NOPAT Margin	-11.62%	-25.51%	-25.05%	0.85%	-10.51%	-3.45%	0.59%	-13.78%	-25.84%	-10.41%	7.89%
Net Nonoperating Expense Percent (NNEP)	-3.04%	-5.67%	-10.09%	0.66%	-4.01%	-4.85%	0.05%	-4.26%	3.54%	50.30%	32.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-11.35%	-6.40%	5.61%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	42.44%	37.23%	44.35%	41.86%	37.60%	40.02%	35.55%	32.75%
SG&A Expenses to Revenue	91.17%	116.98%	115.17%	43.33%	63.38%	48.47%	45.19%	53.63%	61.94%	54.05%	45.92%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	116.60%	136.44%	135.78%	56.71%	77.78%	60.58%	57.56%	82.08%	93.90%	79.33%	56.57%
Earnings before Interest and Taxes (EBIT)	-0.60	-1.58	-2.13	0.18	-4.33	-2.35	0.38	-12	-28	-14	12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.26	-1.35	-1.81	0.50	-3.15	-0.38	2.34	-10	-25	-8.39	17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.22	4.94	2.05	7.05	3.06	9.25	8.36	2.37	1.94	0.76	1.82
Price to Tangible Book Value (P/TBV)	4.86	5.77	2.35	13.52	5.51	15.04	9.75	2.99	17.51	6.21	8.29
Price to Revenue (P/Rev)	10.49	8.90	2.14	6.14	5.59	10.67	17.93	4.78	3.43	0.97	2.13
Price to Earnings (P/E)	0.00	0.00	0.00	574.95	0.00	0.00	2,906.16	0.00	0.00	0.00	45.39
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.17%	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%	2.20%
Enterprise Value to Invested Capital (EV/IC)	40.18	40.62	6.96	12.70	4.56	11.44	14.00	4.32	1.80	0.79	1.80
Enterprise Value to Revenue (EV/Rev)	8.21	7.28	1.28	5.72	4.82	10.42	16.54	3.60	3.74	1.18	2.15
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	244.09	0.00	0.00	432.74	0.00	0.00	0.00	13.58
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	672.97	0.00	0.00	2,682.18	0.00	0.00	0.00	19.78
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	672.97	0.00	0.00	2,808.29	0.00	0.00	0.00	27.24
Enterprise Value to Operating Cash Flow (EV/OCF)	57.33	0.00	0.00	152.95	0.00	0.00	1,396.72	21.08	0.00	22.16	12.57
Enterprise Value to Free Cash Flow (EV/FCFF)	2,954.71	0.00	0.00	0.00	0.00	0.00	0.00	18.95	0.00	37.31	16.26
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.28	0.20
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.26	0.17
Financial Leverage	-0.86	-0.91	-0.87	-0.57	-0.44	-0.31	-0.38	-0.52	-0.20	0.17	0.09
Leverage Ratio	1.43	1.42	1.51	1.41	1.29	1.23	1.11	1.07	1.26	1.46	1.42
Compound Leverage Factor	1.42	1.38	1.50	1.77	1.20	1.16	1.11	1.00	1.13	2.08	0.83
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.26%	21.90%	16.68%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.23%	1.34%	2.76%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	21.03%	20.57%	13.91%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	77.74%	78.10%	83.32%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.42	-3.91	1.48
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.88	-2.32	0.13
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.35	-3.67	1.24
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.96	-3.42	2.97
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.21	-2.03	0.27
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.85	-3.21	2.48
Altman Z-Score	4.57	3.48	-1.66	11.57	6.81	26.99	69.63	21.47	2.22	0.82	3.38
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.30	2.78	2.49	3.72	4.44	3.28	12.29	11.74	3.04	2.89	3.04
Quick Ratio	3.28	2.75	2.41	3.63	4.30	2.83	11.69	11.47	2.80	2.77	2.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.01	-1.15	-1.81	-8.27	-19	-15	-33	12	-115	2.90	14
Operating Cash Flow to CapEx	25,176.44%	-261.14%	-3,503.14%	2,306.49%	-1,893.36%	-5,594.66%	156.31%	4,356.34%	-840.88%	1,086.44%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-79.40	0.47	2.73
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-4.98	0.79	3.54
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-5.57	0.72	3.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.36	0.56	1.22	0.60	0.74	0.61	0.45	0.45	0.52	0.63
Accounts Receivable Turnover	1.45	1.47	1.83	4.29	3.55	3.42	2.87	2.66	2.45	2.47	2.88
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	312.21	47.20	34.92	133.95	151.21	266.65	418.85	444.06	499.37	616.23	854.91
Accounts Payable Turnover	0.00	0.00	0.00	20.73	20.26	34.57	41.88	21.78	15.16	14.94	18.90
Days Sales Outstanding (DSO)	250.93	248.43	199.01	85.10	102.95	106.62	127.10	137.22	149.04	147.51	126.69
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	17.61	18.01	10.56	8.71	16.76	24.08	24.43	19.31
Cash Conversion Cycle (CCC)	250.93	248.43	199.01	67.49	84.93	96.06	118.38	120.46	124.96	123.09	107.38
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.73	0.78	1.10	9.54	26	39	72	52	149	136	131
Invested Capital Turnover	3.79	5.74	6.35	3.99	1.38	1.32	1.10	1.00	0.71	0.65	0.82
Increase / (Decrease) in Invested Capital	-0.43	0.04	0.32	8.45	16	13	33	-20	97	-12	-5.83
Enterprise Value (EV)	30	32	7.64	121	119	452	1,014	225	267	108	235
Market Capitalization	38	39	13	130	137	462	1,099	299	245	89	233
Book Value per Share	$0.31	$0.26	$0.21	$1.54	$3.17	$3.31	$7.39	$7.35	$6.97	$6.40	$6.88
Tangible Book Value per Share	$0.27	$0.23	$0.19	$0.80	$1.76	$2.03	$6.34	$5.83	$0.77	$0.78	$1.51
Total Capital	8.94	7.81	6.22	18	45	50	131	126	163	150	154
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	36	33	26
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	34	31	21
Net Debt	-8.21	-7.03	-5.12	-8.91	-19	-11	-85	-74	22	19	2.31
Capital Expenditures (CapEx)	0.00	0.18	0.04	0.03	0.09	0.11	0.46	0.24	0.86	0.45	-0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.45	-0.53	0.14	2.59	2.18	12	21	16	25	24	24
Debt-free Net Working Capital (DFNWC)	7.75	6.51	5.27	12	21	23	106	90	38	37	48
Net Working Capital (NWC)	7.75	6.51	5.27	12	21	23	106	90	36	35	43
Net Nonoperating Expense (NNE)	0.18	0.43	0.61	-0.05	0.56	0.71	-0.02	2.83	-0.92	11	3.50
Net Nonoperating Obligations (NNO)	-8.21	-7.03	-5.12	-8.91	-19	-11	-59	-74	22	19	2.31
Total Depreciation and Amortization (D&A)	0.33	0.24	0.32	0.32	1.18	1.97	1.97	2.02	2.61	5.16	5.44
Debt-free, Cash-free Net Working Capital to Revenue	-12.61%	-12.11%	2.40%	12.20%	8.87%	28.43%	34.36%	25.68%	34.39%	25.98%	22.24%
Debt-free Net Working Capital to Revenue	215.48%	149.98%	88.46%	54.23%	85.51%	52.71%	172.52%	144.40%	53.76%	40.51%	43.60%
Net Working Capital to Revenue	215.48%	149.98%	88.46%	54.23%	85.51%	52.71%	172.52%	144.40%	50.96%	38.34%	39.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	($0.05)	($0.07)	$0.02	$0.00	($0.15)	$0.00	($0.64)	($1.03)	($1.10)	$0.28
Adjusted Weighted Average Basic Shares Outstanding	24.56M	29.71M	29.32M	10.83M	13.39M	14.83M	0.00	17.78M	17.12M	18.29M	18.56M
Adjusted Diluted Earnings per Share	($0.02)	($0.05)	($0.07)	$0.02	$0.00	($0.15)	$0.00	($0.64)	($1.03)	($1.10)	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	29.03M	29.72M	29.32M	11.86M	13.39M	14.83M	0.00	17.78M	17.12M	18.29M	19.00M
Adjusted Basic & Diluted Earnings per Share	($0.02)	($0.05)	($0.07)	$0.02	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.03M	29.72M	29.46M	12.10M	14.64M	16.81M	0.00	17.10M	0.00	0.00	18.76M
Normalized Net Operating Profit after Tax (NOPAT)	-0.42	-1.07	-1.49	0.13	-2.59	-1.49	4.10	2.42	-4.16	3.68	8.91
Normalized NOPAT Margin	-11.62%	-24.70%	-25.05%	0.59%	-10.51%	-3.45%	6.68%	3.87%	-5.82%	3.99%	8.14%
Pre Tax Income Margin	-16.54%	-35.47%	-35.35%	1.07%	-16.43%	-5.10%	0.62%	-18.32%	-35.18%	-21.04%	6.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-19.29	-2.20	2.25
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.71	-1.56	1.63
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-19.88	-2.27	2.26
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-13.30	-1.63	1.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-52.42%	-18.54%	0.00%	0.00%	0.00%	0.00%	-175.06%	-42.82%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	16,637,891.00	18,152,478.00	18,152,478.00	18,152,478.00	18,152,478.00	-	18,152,478.00	18,495,111.00	18,565,033.00	18,640,652.00	18,762,203.00
DEI Adjusted Shares Outstanding	16,637,891.00	18,152,478.00	18,152,478.00	18,152,478.00	18,152,478.00	-	18,152,478.00	18,495,111.00	18,565,033.00	18,640,652.00	18,762,203.00
DEI Earnings Per Adjusted Shares Outstanding	-0.17	-0.23	-0.38	-0.22	-0.50	-	-0.12	0.08	0.04	0.27	-0.03
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.26%	44.34%	51.43%	36.14%	30.48%	13.91%	11.37%	55.19%	22.33%	-0.24%	-9.50%
EBITDA Growth	-4.61%	-1,246.89%	42.72%	44.84%	-134.76%	151.61%	78.97%	295.91%	146.46%	98.44%	333.46%
EBIT Growth	-2.49%	-828.33%	28.80%	24.23%	-139.91%	133.23%	58.98%	187.81%	124.78%	134.90%	121.04%
NOPAT Growth	5.42%	-1,165.35%	28.80%	22.69%	-140.98%	98.30%	58.20%	208.68%	125.40%	4,525.24%	118.84%
Net Income Growth	17.36%	-1,171.19%	-7.83%	3.68%	-218.46%	98.09%	68.13%	138.22%	108.54%	6,454.43%	77.49%
EPS Growth	10.53%	-733.33%	-2.70%	8.33%	-194.12%	0.00%	68.42%	136.36%	108.00%	0.00%	75.00%
Operating Cash Flow Growth	-57.46%	-323.22%	2,562.79%	133.01%	21.59%	103.16%	82.44%	483.25%	78.78%	3,479.80%	-112.09%
Free Cash Flow Firm Growth	70.13%	-627.01%	-634.93%	-2,889.73%	-2,426.18%	111.82%	109.79%	114.52%	104.89%	-6.33%	-103.40%
Invested Capital Growth	1.95%	186.57%	184.68%	166.59%	158.12%	-8.39%	-7.62%	-7.32%	-2.07%	-4.27%	0.45%
Revenue Q/Q Growth	18.19%	73.72%	-30.60%	-4.46%	13.27%	51.65%	-32.15%	33.14%	-10.71%	23.68%	-38.45%
EBITDA Q/Q Growth	29.58%	-214.84%	61.11%	36.03%	-199.71%	169.21%	-115.73%	686.99%	-28.92%	197.92%	-81.50%
EBIT Q/Q Growth	26.73%	-207.82%	54.02%	26.94%	-132.01%	142.63%	-156.17%	255.47%	-34.53%	308.52%	-94.97%
NOPAT Q/Q Growth	26.73%	-207.82%	54.02%	25.45%	-128.38%	97.83%	-1,031.15%	292.73%	-46.62%	278.12%	-95.18%
Net Income Q/Q Growth	31.15%	-44.57%	-66.56%	41.90%	-127.64%	99.13%	-2,683.54%	169.67%	-49.15%	544.42%	-109.86%
EPS Q/Q Growth	29.17%	-47.06%	-52.00%	42.11%	-127.27%	0.00%	0.00%	166.67%	-50.00%	575.00%	-111.11%
Operating Cash Flow Q/Q Growth	162.18%	-524.85%	133.84%	-63.08%	129.03%	-88.94%	1,851.52%	18.04%	-29.80%	121.36%	-106.59%
Free Cash Flow Firm Q/Q Growth	-14.20%	-2,908.49%	7.91%	5.51%	3.51%	114.08%	-23.77%	40.29%	-67.51%	169.78%	-102.77%
Invested Capital Q/Q Growth	-2.47%	187.71%	-3.92%	-1.12%	-5.56%	2.11%	-3.11%	-0.80%	-0.21%	-0.18%	1.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.01%	62.89%	61.98%	62.22%	63.10%	68.15%	60.85%	63.83%	67.20%	74.75%	75.25%
EBITDA Margin	-18.90%	-34.26%	-19.20%	-12.85%	-34.01%	15.52%	-3.63%	16.23%	12.92%	31.11%	9.35%
Operating Margin	-21.76%	-38.55%	-25.54%	-19.93%	-40.18%	11.25%	-9.59%	10.92%	7.86%	26.58%	2.00%
EBIT Margin	-21.76%	-38.55%	-25.54%	-19.53%	-40.00%	11.25%	-9.41%	11.05%	8.10%	26.76%	2.19%
Profit (Net Income) Margin	-17.54%	-14.60%	-35.04%	-21.31%	-42.82%	-0.24%	-10.03%	5.25%	2.99%	15.57%	-2.49%
Tax Burden Percent	100.00%	35.18%	105.25%	78.65%	91.78%	-3.58%	67.21%	89.43%	74.26%	67.18%	76.86%
Interest Burden Percent	80.64%	107.64%	130.34%	138.70%	116.62%	60.73%	158.60%	53.10%	49.67%	86.60%	-148.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	103.58%	0.00%	10.57%	25.74%	32.82%	0.00%
Return on Invested Capital (ROIC)	-18.66%	-19.21%	-14.46%	-11.93%	-26.76%	-0.26%	-4.60%	7.51%	4.84%	14.63%	1.13%
ROIC Less NNEP Spread (ROIC-NNEP)	-18.13%	-32.79%	-1.75%	-5.38%	-12.90%	-0.02%	-8.59%	-0.66%	-0.52%	7.86%	-6.96%
Return on Net Nonoperating Assets (RNNOA)	10.56%	6.72%	0.38%	0.96%	2.53%	0.00%	-1.31%	-0.09%	-0.06%	0.70%	-0.54%
Return on Equity (ROE)	-8.09%	-12.50%	-14.09%	-10.97%	-24.23%	-0.26%	-5.91%	7.42%	4.78%	15.33%	0.59%
Cash Return on Invested Capital (CROIC)	-24.23%	-114.92%	-113.66%	-107.63%	-109.66%	2.04%	2.44%	5.62%	2.20%	10.83%	7.19%
Operating Return on Assets (OROA)	-10.52%	-17.34%	-12.97%	-11.05%	-24.40%	5.84%	-5.16%	6.77%	5.29%	16.83%	1.40%
Return on Assets (ROA)	-8.48%	-6.57%	-17.79%	-12.05%	-26.12%	-0.13%	-5.50%	3.21%	1.95%	9.79%	-1.60%
Return on Common Equity (ROCE)	-8.09%	-12.50%	-14.09%	-10.97%	-24.23%	-0.26%	-5.91%	7.42%	4.78%	15.33%	0.59%
Return on Equity Simple (ROE_SIMPLE)	-11.84%	0.00%	-14.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.49	-7.66	-3.52	-2.62	-5.99	-0.13	-1.47	2.85	1.52	5.76	0.28
NOPAT Margin	-15.23%	-26.99%	-17.88%	-13.95%	-28.13%	-0.40%	-6.71%	9.77%	5.84%	17.86%	1.40%
Net Nonoperating Expense Percent (NNEP)	-0.53%	13.58%	-12.71%	-6.55%	-13.86%	-0.24%	3.99%	8.17%	5.36%	6.77%	8.09%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.70%	-2.22%	-1.67%	-4.00%	-0.09%	-0.99%	1.93%	1.01%	3.74%	0.18%
Cost of Revenue to Revenue	39.99%	37.11%	38.02%	37.78%	36.90%	31.85%	39.15%	36.17%	32.80%	25.25%	24.75%
SG&A Expenses to Revenue	78.91%	18.24%	82.10%	76.44%	63.00%	18.03%	20.78%	49.23%	55.19%	22.09%	17.70%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.83%	0.00%	0.00%	0.00%	17.14%
Operating Expenses to Revenue	81.76%	93.89%	87.52%	82.14%	103.29%	56.90%	70.44%	52.91%	59.33%	48.18%	73.25%
Earnings before Interest and Taxes (EBIT)	-3.55	-11	-5.03	-3.67	-8.52	3.63	-2.06	3.23	2.11	8.63	0.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.09	-9.72	-3.78	-2.42	-7.25	5.02	-0.80	4.74	3.37	10	1.86
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.11	1.94	1.80	1.51	1.24	0.76	1.38	2.15	3.26	1.82	0.91
Price to Tangible Book Value (P/TBV)	1.46	17.51	0.00	0.00	25.72	6.21	18.12	20.37	24.42	8.29	4.61
Price to Revenue (P/Rev)	2.06	3.43	2.82	2.19	1.60	0.97	1.70	2.45	3.64	2.13	1.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12,088.71	45.39	17.24
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	2.20%	5.80%
Enterprise Value to Invested Capital (EV/IC)	1.26	1.80	1.69	1.44	1.20	0.79	1.33	2.05	3.11	1.80	0.91
Enterprise Value to Revenue (EV/Rev)	1.04	3.74	3.09	2.44	1.82	1.18	1.86	2.56	3.72	2.15	1.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	154.52	32.99	13.58	6.06
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	58.75	19.78	8.41
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,078.51	27.24	11.95
Enterprise Value to Operating Cash Flow (EV/OCF)	35.74	0.00	0.00	0.00	0.00	22.16	26.51	25.79	34.46	12.57	8.41
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	37.31	52.43	35.03	140.31	16.26	12.70
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.29	0.30	0.30	0.31	0.28	0.28	0.24	0.23	0.20	0.18
Long-Term Debt to Equity	0.00	0.27	0.27	0.27	0.29	0.26	0.25	0.21	0.20	0.17	0.16
Financial Leverage	-0.58	-0.20	-0.22	-0.18	-0.20	0.17	0.15	0.13	0.12	0.09	0.08
Leverage Ratio	1.06	1.26	1.25	1.24	1.25	1.46	1.44	1.42	1.42	1.42	1.36
Compound Leverage Factor	0.85	1.35	1.63	1.72	1.46	0.88	2.29	0.76	0.70	1.23	-2.02
Debt to Total Capital	0.00%	22.26%	22.82%	22.86%	23.56%	21.90%	21.84%	19.25%	18.69%	16.68%	15.26%
Short-Term Debt to Total Capital	0.00%	1.23%	2.20%	2.10%	1.34%	1.34%	2.22%	2.23%	2.19%	2.76%	1.31%
Long-Term Debt to Total Capital	0.00%	21.03%	20.61%	20.76%	22.22%	20.57%	19.62%	17.01%	16.49%	13.91%	13.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	77.74%	77.18%	77.14%	76.44%	78.10%	78.16%	80.76%	81.31%	83.32%	84.74%
Debt to EBITDA	0.00	-1.42	-1.73	-1.88	-1.52	-3.91	-6.01	16.36	2.28	1.48	1.17
Net Debt to EBITDA	0.00	-0.88	-0.98	-1.07	-0.82	-2.32	-2.94	6.81	0.69	0.13	0.16
Long-Term Debt to EBITDA	0.00	-1.35	-1.56	-1.71	-1.43	-3.67	-5.40	14.46	2.01	1.24	1.07
Debt to NOPAT	0.00	-1.96	-2.12	-2.20	-1.78	-3.42	-4.31	-10.54	212.29	2.97	2.30
Net Debt to NOPAT	0.00	-1.21	-1.20	-1.26	-0.97	-2.03	-2.11	-4.39	64.83	0.27	0.31
Long-Term Debt to NOPAT	0.00	-1.85	-1.92	-2.00	-1.68	-3.21	-3.87	-9.32	187.36	2.48	2.11
Altman Z-Score	10.43	2.53	2.46	2.13	1.56	1.15	1.90	3.29	5.24	3.32	2.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.35	3.04	2.88	3.07	3.23	2.89	2.82	2.57	3.05	3.04	5.37
Quick Ratio	10.96	2.80	2.68	2.64	2.93	2.77	2.69	2.38	2.80	2.87	4.99
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.48	-105	-96	-91	-88	12	9.43	13	4.29	12	-0.32
Operating Cash Flow to CapEx	460.31%	0.00%	1,384.31%	920.00%	1,946.74%	165.00%	4,600.00%	10,365.91%	32,020.00%	0.00%	-2,223.81%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-62.32	-59.58	-57.64	7.92	7.27	8.24	3.72	9.34	-0.28
Operating Cash Flow to Interest Expense	0.00	0.00	1.37	0.51	1.18	0.13	2.98	2.85	2.77	5.72	-0.40
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	1.27	0.46	1.11	0.05	2.91	2.82	2.77	5.88	-0.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.45	0.51	0.57	0.61	0.52	0.55	0.61	0.65	0.63	0.64
Accounts Receivable Turnover	3.25	2.45	3.26	3.89	3.74	2.47	3.02	3.61	3.74	2.88	3.32
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	428.15	499.37	526.79	533.41	568.35	616.23	622.87	686.87	782.19	854.91	835.37
Accounts Payable Turnover	29.90	15.16	20.68	16.67	19.15	14.94	13.42	15.03	15.86	18.90	9.98
Days Sales Outstanding (DSO)	112.31	149.04	111.80	93.88	97.61	147.51	120.81	101.11	97.58	126.69	110.01
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	12.21	24.08	17.65	21.90	19.06	24.43	27.21	24.28	23.02	19.31	36.58
Cash Conversion Cycle (CCC)	100.11	124.96	94.15	71.99	78.55	123.09	93.60	76.83	74.57	107.38	73.43
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	52	149	143	141	134	136	132	131	131	131	133
Invested Capital Turnover	1.23	0.71	0.81	0.86	0.95	0.65	0.69	0.77	0.83	0.82	0.81
Increase / (Decrease) in Invested Capital	0.99	97	93	88	82	-12	-11	-10	-2.77	-5.83	0.60
Enterprise Value (EV)	65	267	241	203	161	108	176	269	408	235	121
Market Capitalization	129	245	221	183	141	89	160	257	399	233	118
Book Value per Share	$6.98	$6.97	$6.75	$6.63	$6.25	$6.40	$6.29	$6.45	$6.59	$6.88	$6.91
Tangible Book Value per Share	$5.32	$0.77	($0.24)	($0.26)	$0.30	$0.78	$0.48	$0.68	$0.88	$1.51	$1.36
Total Capital	116	163	159	157	150	150	149	148	150	154	153
Total Debt	0.00	36	36	36	35	33	32	28	28	26	23
Total Long-Term Debt	0.00	34	33	33	33	31	29	25	25	21	21
Net Debt	-64	22	21	20	19	19	16	12	8.58	2.31	3.17
Capital Expenditures (CapEx)	0.32	-0.77	0.15	0.09	0.09	0.12	0.08	0.04	0.01	-0.21	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	16	25	20	19	18	24	20	20	22	24	28
Debt-free Net Working Capital (DFNWC)	80	38	35	34	34	37	37	36	41	48	48
Net Working Capital (NWC)	80	36	32	31	32	35	33	33	38	43	46
Net Nonoperating Expense (NNE)	0.38	-3.51	3.38	1.38	3.13	-0.05	0.73	1.32	0.74	0.74	0.77
Net Nonoperating Obligations (NNO)	-64	22	21	20	19	19	16	12	8.58	2.31	3.17
Total Depreciation and Amortization (D&A)	0.47	1.22	1.25	1.26	1.28	1.38	1.27	1.51	1.26	1.40	1.42
Debt-free, Cash-free Net Working Capital to Revenue	25.71%	34.39%	25.46%	23.26%	20.73%	25.98%	21.29%	18.84%	19.76%	22.24%	25.65%
Debt-free Net Working Capital to Revenue	126.88%	53.76%	44.86%	41.24%	39.02%	40.51%	38.85%	34.68%	37.58%	43.60%	44.44%
Net Working Capital to Revenue	126.88%	50.96%	40.39%	37.27%	36.75%	38.34%	35.35%	31.53%	34.57%	39.71%	42.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.17)	($0.25)	($0.38)	($0.22)	($0.50)	$0.00	($0.12)	$0.08	$0.04	$0.28	($0.03)
Adjusted Weighted Average Basic Shares Outstanding	16.64M	17.12M	18.17M	18.26M	18.32M	18.29M	18.47M	18.51M	18.58M	18.56M	18.76M
Adjusted Diluted Earnings per Share	($0.17)	($0.25)	($0.38)	($0.22)	($0.50)	$0.00	($0.12)	$0.08	$0.04	$0.27	($0.03)
Adjusted Weighted Average Diluted Shares Outstanding	16.64M	17.12M	18.17M	18.26M	18.32M	18.29M	18.47M	19.02M	19.46M	19.00M	18.76M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	18.15M	0.00	18.27M	18.32M	0.00	0.00	18.50M	18.57M	18.64M	18.76M	18.77M
Normalized Net Operating Profit after Tax (NOPAT)	-2.49	-7.66	-3.52	-2.62	-0.75	2.54	-1.47	2.85	1.52	5.76	0.28
Normalized NOPAT Margin	-15.23%	-26.99%	-17.88%	-13.95%	-3.52%	7.87%	-6.71%	9.77%	5.84%	17.86%	1.40%
Pre Tax Income Margin	-17.54%	-41.50%	-33.29%	-27.09%	-46.65%	6.83%	-14.92%	5.87%	4.02%	23.18%	-3.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-3.25	-2.40	-5.59	2.33	-1.59	2.01	1.83	6.96	0.38
NOPAT to Interest Expense	0.00	0.00	-2.28	-1.72	-3.93	-0.08	-1.13	1.78	1.32	4.64	0.24
EBIT Less CapEx to Interest Expense	0.00	0.00	-3.35	-2.46	-5.65	2.25	-1.66	1.99	1.82	7.12	0.36
NOPAT Less CapEx to Interest Expense	0.00	0.00	-2.38	-1.77	-3.99	-0.16	-1.20	1.75	1.31	4.81	0.22
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-108.98%	-42.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

OptimizeRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OptimizeRx's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

OptimizeRx's net income appears to be on an upward trend, with a most recent value of $5.13 million in 2025, falling from -$595.14 thousand in 2015. The previous period was -$20.11 million in 2024. Find out what analysts predict for OptimizeRx in the coming months.

OptimizeRx's total operating income in 2025 was $11.69 million, based on the following breakdown:

Total Gross Profit: $73.60 million
Total Operating Expenses: $61.90 million

Over the last 10 years, OptimizeRx's total revenue changed from $3.60 million in 2015 to $109.43 million in 2025, a change of 2,941.0%.

OptimizeRx's total liabilities were at $48.62 million at the end of 2025, a 10.2% decrease from 2024, and a 1,342.1% increase since 2015.

In the past 10 years, OptimizeRx's cash and equivalents has ranged from $5.12 million in 2017 to $84.68 million in 2021, and is currently $23.37 million as of their latest financial filing in 2025.

Over the last 10 years, OptimizeRx's book value per share changed from 0.31 in 2015 to 6.88 in 2025, a change of 2,133.1%.

Related Companies

Financial statements for NASDAQ:OPRX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Financials

Financials Breakdown Chart

OptimizeRx Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OptimizeRx (OPRX) Financials

Annual Income Statements for OptimizeRx

Quarterly Income Statements for OptimizeRx

Annual Cash Flow Statements for OptimizeRx

Quarterly Cash Flow Statements for OptimizeRx

Annual Balance Sheets for OptimizeRx

Quarterly Balance Sheets for OptimizeRx

Annual Metrics And Ratios for OptimizeRx

Quarterly Metrics And Ratios for OptimizeRx

Financials Breakdown Chart

OptimizeRx Financials - Frequently Asked Questions

When does OptimizeRx's fiscal year end?

How has OptimizeRx's net income changed over the last 10 years?

What is OptimizeRx's operating income?

How has OptimizeRx's revenue changed over the last 10 years?

How much debt does OptimizeRx have?

How much cash does OptimizeRx have?

How has OptimizeRx's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools